Logo-bi
Bioimpacts. 2018;8(3): 211-221. doi: 10.15171/bi.2018.24
PMID: 30211081        PMCID: PMC6128972

Original Research

A cancer vaccine with dendritic cells differentiated with GM-CSF and IFNα and pulsed with a squaric acid treated cell lysate improves T cell priming and tumor growth control in a mouse model

Ananda Mookerjee 1, Michele Graciotti 2, Lana E. Kandalaft 1,2 *

Cited by CrossRef: 21

1- Abbaspour M, Esmaeil N, Rezazadeh M, Minaiyan M, Akbari V. DCs pulsed with hypochlorous acid-treated tumor cell lysates present antigens efficiently and induce CD8+ T cell activation through cross-presentation. 2025;20(2):230 [Crossref]
2- Faure F, Yshii L, Renno T, coste I, Joubert B, Desestret V, Liblau R, Honnorat J. A Pilot Study to Develop Paraneoplastic Cerebellar Degeneration Mouse Model. Cerebellum. 2023;23(1):181 [Crossref]
3- Roufarshbaf M, Esmaeil N, Akbari V. Comparison of four methods of colon cancer cell lysates preparation for ex vivo maturation of dendritic cells. 2022;17(1):43 [Crossref]
4- Hamdan F, Fusciello M, Cerullo V. Personalizing Oncolytic Virotherapy. Human Gene Therapy. 2023;34(17-18):870 [Crossref]
5- Guo X, Zhang T, Wang X, Su H, Sun W, Liu Y, Kang K, Liu T, Jiang S, Wang Y, Wang D, Yin H, Tian L, Li D, Ren G. The immune enhancement effects of recombinant NDV expressing chicken granulocyte-macrophage colony-stimulating factor on the different avian influenza vaccine subtypes. Transbound Emerg Dis. 2020; [Crossref]
6- Graciotti M, Marino F, Pak H, Baumgaertner P, Thierry A, Chiffelle J, Perez M, Zoete V, Harari A, Bassani-Sternberg M, Kandalaft L. Deciphering the Mechanisms of Improved Immunogenicity of Hypochlorous Acid-Treated Antigens in Anti-Cancer Dendritic Cell-Based Vaccines. Vaccines. 2020;8(2):271 [Crossref]
7- Priya Vadhana K, Parveen S, Ushadevi B, Selvakumar R, Sangeetha S, Vairam S. New barium, strontium and strontium-doped barium squarates: synthesis, crystal structures and DNA/BSA binding, antioxidant and in vitro cytotoxicity studies. Acta Crystallogr C Struct Chem. 2019;75(8):1091 [Crossref]
8- Harari A, Graciotti M, Bassani-Sternberg M, Kandalaft L. Antitumour dendritic cell vaccination in a priming and boosting approach. Nat Rev Drug Discov. 2020;19(9):635 [Crossref]
9- Bhargava A, Srivastava R, Mishra D, Tiwari R, Sharma R, Mishra P. Dendritic cell engineering for selective targeting of female reproductive tract cancers. 2018;148(Suppl 1):S50 [Crossref]
10- Mookerjee A, Graciotti M, Kandalaft L. IL-15 and a Two-Step Maturation Process Improve Bone Marrow-Derived Dendritic Cell Cancer Vaccine. Cancers. 2019;11(1):40 [Crossref]
11- Putting into Perspective the Future of Cancer Vaccines: Targeted Immunotherapy. EMJ. 2020; [Crossref]
12- Li X, Wang J, Wu W, Gao H, Liu N, Zhan G, Li L, Han L, Guo X. Myeloid‐derived suppressor cells promote epithelial ovarian cancer cell stemness by inducing the CSF2/p‐STAT3 signalling pathway. The FEBS Journal. 2020;287(23):5218 [Crossref]
13- Martin-Lluesma S, Graciotti M, Grimm A, Boudousquié C, Chiang C, Kandalaft L. Are dendritic cells the most appropriate therapeutic vaccine for patients with ovarian cancer?. Current Opinion in Biotechnology. 2020;65:190 [Crossref]
14- Hashemzadeh N, Dolatkhah M, Adibkia K, Aghanejad A, Barzegar-Jalali M, Omidi Y, Barar J. Recent advances in breast cancer immunotherapy: The promising impact of nanomedicines. Life Sciences. 2021;271:119110 [Crossref]
15- Seong J, Jeong S, Kim S, Yun S, Baek Y, Kim K. Ex vivo activation of dendritic cells via coacervate-mediated exogenous tumor cell lysate delivery. Biomater Sci. 2023;11(13):4537 [Crossref]
16- Lozano M, Cid J, Benitez-Ribas D, Otero M. Technical Challenges in the Manufacture of Dendritic Cell Cancer Therapies. 2019;15(1):22 [Crossref]
17- Martin Lluesma S, Graciotti M, Chiang C, Kandalaft L. Does the Immunocompetent Status of Cancer Patients Have an Impact on Therapeutic DC Vaccination Strategies?. Vaccines. 2018;6(4):79 [Crossref]
18- Priya Vadhana K, Vairam S, Ushadevi B, Parveen S. New Mg(II) and Ca(II) Mixed Strontium Squarates: Structural Characterization, DNA/BSA Interaction, Antioxidant and Anticancer Activities. J Clust Sci. 2022;33(3):867 [Crossref]
19- Seong J, Kim K. Activation of Cellular Players in Adaptive Immunity via Exogenous Delivery of Tumor Cell Lysates. Pharmaceutics. 2022;14(7):1358 [Crossref]
20- Li L, Zhou J, Dong X, Liao Q, Zhou D, Zhou Y. Dendritic cell vaccines for glioblastoma fail to complete clinical translation: Bottlenecks and potential countermeasures. International Immunopharmacology. 2022;109:108929 [Crossref]
21- Clemen R, Bekeschus S. ROS Cocktails as an Adjuvant for Personalized Antitumor Vaccination?. Vaccines. 2021;9(5):527 [Crossref]

As a peer-reviewed international open-access journal, BioImpacts publishes articles on basic and translational aspects of pharmaceutical and biomedical sciences. 
Acceptance rate (2024): 20% 
Publication fee: Free of charge

Indexing/Abstracting Info
PubMed; PubMed Central; Scopus; Science Citation Index Expanded; Google Scholar;   SJR; Essential Science Indicators; Embase; EBSCOhost; CAS: DOAJ: SHERPA/RoMEO
Member of   
Follower of ICMJE
Permission: Creative Commons